GSK plc (NYSE: GSK) sees Ris-Rez hit phase III goal in relapsed osteosarcoma
Rhea-AI Filing Summary
GSK plc reported that its licensor Hansoh Pharmaceutical Group’s pivotal phase III ARTEMIS-011 trial of risvutatug rezetecan (Ris-Rez) in Chinese patients with relapsed osteosarcoma who had received at least two prior systemic therapies met its primary endpoint of progression-free survival. Ris-Rez, a B7-H3-targeted antibody-drug conjugate, produced statistically significant and clinically meaningful improvements in progression-free survival compared with chemotherapy, with consistent benefit across secondary endpoints including overall survival. The safety profile was consistent with prior findings in this tumour type, with no new safety signals, and Hansoh plans to use these data for regulatory submission in China.
GSK holds exclusive rights to develop and commercialise Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan and is running the global EMBOLD Sarcoma-202 phase Ib/II trial in advanced or metastatic sarcomas as part of a broader solid-tumour programme including lung and prostate cancers. Ris-Rez has multiple regulatory designations, including US FDA Breakthrough Therapy Designation in relapsed or refractory extensive-stage small-cell lung cancer and relapsed or refractory osteosarcoma, EMA PRIME and orphan drug designations, and is described as the only B7-H3-targeted ADC with positive phase III outcomes across multiple tumour types. Osteosarcoma mainly affects children and young adults, represents 20-40% of primary bone cancers, and has a global incidence of about 3.4 cases per million people per year, with very limited options after failure of first-line chemotherapy.
Positive
- The pivotal ARTEMIS-011 phase III trial of Ris-Rez in relapsed osteosarcoma met its primary endpoint, showing statistically significant and clinically meaningful progression-free survival benefit versus chemotherapy and providing late-stage evidence that can support Hansoh’s planned regulatory submission in China while expanding GSK’s oncology portfolio exposure.
Negative
- None.
Key Figures
Osteosarcoma share of bone cancers: 20-40% of all bone cancers
Osteosarcoma global incidence: 3.4 cases per million people per year
Prior treatment requirement in ARTEMIS-011: at least two prior lines of systemic therapy
+1 more
4 metrics
Osteosarcoma share of bone cancers
20-40% of all bone cancers
Proportion of primary bone cancer cases attributed to osteosarcoma
Osteosarcoma global incidence
3.4 cases per million people per year
Estimated worldwide incidence of osteosarcoma
Prior treatment requirement in ARTEMIS-011
at least two prior lines of systemic therapy
Eligibility criterion for relapsed osteosarcoma patients in the phase III trial
GSK risk factor reference year
2025
Year of GSK Annual Report on Form 20-F cited for risk factors
Key Terms
progression-free survival, antibody-drug conjugate (ADC), Breakthrough Therapy Designation, orphan drug designations, +1 more
5 terms
progression-free survival medical
"met its primary endpoint of progression-free survival in relapsed osteosarcoma"
Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.
antibody-drug conjugate (ADC) medical
"Ris-Rez, a B7-H3-targeted antibody-drug conjugate (ADC), demonstrated statistically significant"
An antibody-drug conjugate (ADC) is a targeted medical treatment that combines an antibody, which acts like a guided missile seeking out specific cells, with a powerful drug to destroy those cells. It is designed to deliver medication directly to diseased cells, minimizing damage to healthy tissue. For investors, ADCs represent innovative therapies with potential for high growth, especially if they prove effective in treating difficult-to-cure conditions.
Breakthrough Therapy Designation regulatory
"Ris-Rez has US FDA Breakthrough Therapy Designation in relapsed or refractory osteosarcoma"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
orphan drug designations regulatory
"Regulatory designations received for Ris-Rez to date include orphan drug designations"
A regulatory status granted to medicines that treat rare diseases, giving developers special incentives and protections — for example, reduced fees, tax benefits, and a period of exclusive marketing once approved. Think of it as a government “boost” that lowers development costs and shields a product from direct competition for a time; investors watch for it because it can raise a drug’s commercial value and reduce the financial risk of bringing a treatment for a small patient group to market.
Priority Medicines (PRIME) Designation regulatory
"Priority Medicines (PRIME) Designation from the EMA for relapsed or refractory ES-SCLC"
A priority medicines (PRIority MEdicines, PRIME) designation is a regulatory label given to a drug candidate that addresses a serious unmet medical need, granting the developer extra scientific guidance and faster review from health authorities. For investors, it signals lower regulatory risk and the potential for quicker approval and market access—think of it as a VIP pass through the approval process that can speed revenue potential and improve the investment outlook.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did GSK (GSK) report about the ARTEMIS-011 phase III trial of Ris-Rez?
GSK highlighted that ARTEMIS-011, Hansoh Pharma’s phase III trial of Ris-Rez in relapsed osteosarcoma, met its primary endpoint of progression-free survival. Ris-Rez showed statistically significant and clinically meaningful PFS improvement versus chemotherapy, with consistent benefit across secondary endpoints including overall survival.
What is Ris-Rez and how is GSK (GSK) involved in its development?
Ris-Rez is an investigational B7-H3-targeted antibody-drug conjugate composed of a fully human anti-B7-H3 antibody linked to a topoisomerase inhibitor payload. GSK has exclusive rights to develop and commercialise Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan under a licence from Hansoh Pharma.
Which regulatory designations has Ris-Rez received according to GSK (GSK)?
Ris-Rez has multiple designations, including US FDA Breakthrough Therapy Designation for relapsed or refractory extensive-stage small-cell lung cancer and osteosarcoma, orphan drug designations from US and Japanese regulators, and EMA PRIME and orphan designations in a category that includes small-cell lung cancer.
What unmet medical need in osteosarcoma does GSK (GSK) highlight?
GSK notes that osteosarcoma mainly affects children and young adults, represents 20-40% of primary bone cancers, and has a global incidence of about 3.4 cases per million annually. After first-line chemotherapy, treatment options are severely limited, with no approved therapies after two prior lines.
What broader clinical programme is GSK (GSK) running for Ris-Rez?
GSK is conducting EMBOLD Sarcoma-202, a global phase Ib/II trial of Ris-Rez in previously treated unresectable advanced or metastatic sarcomas, including osteosarcoma. This study is part of a wider solid-tumour development programme spanning lung, prostate and other cancers under GSK’s ex-China rights.
How does GSK (GSK) describe Ris-Rez among B7-H3-targeted ADCs?
GSK states that, following positive phase III data in small-cell lung cancer and osteosarcoma, Ris-Rez is the only B7-H3-targeted antibody-drug conjugate reported to deliver positive phase III outcomes across multiple tumour types, supporting confidence in B7-H3 as a therapeutic target.